US biotech licenses antibody from Takeda for new kidney drugs

Goldfinch Bio, a US company focused on developing treatments for kidney disease, has agreed to license a cannabinoid receptor 1 (CB1) antibody from Japanese pharmaceutical manufacturer Takeda.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Novo Nordisk takes on Hims & Hers after $49 pill ‘turnaround’

10 February 2026 Telehealth platform faces legal action from the Danish pharma giant, as well as FDA pressure over GLP-1 drugs and a drop in shares after discontinuing new product.

Americas

Novartis takes aim at Tafinlar generic in latest suit

9 February 2026 The Swiss pharma giant moves to protect patents on its billion-dollar cancer therapy following an ANDA filing by a Canadian generics manufacturer.

Americas

Semaglutide patent battle heats up with new blow for Novo in India

6 February 2026 A Delhi High Court ruling signals more bad news for the Danish pharma giant in the same week that it lost nearly $50 billion in value.

More features

New rankings recognise top US patent firms and lawyers

Norton Rose Fulbright expands pharma and biotech disputes team

UPC appeals court confirms ‘all-or-nothing’ rule for unitary patents

Honigman bags second Kirkland litigator this year for IP team

Reaction: Emotional Perception decision is ‘good for UK PLC’

UK ruling ‘future-proofs’ patentability for AI and computer tech

The curtain closes on three major drug disputes

Novo Nordisk takes on Hims & Hers after $49 pill ‘turnaround’

US biotech licenses antibody from Takeda for new kidney drugs

More on this story

Editor's picks

Editor's picks

More features